LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Core Insights - LAVA Therapeutics has received a full waiver of a $5.1 million repayment obligation from the Netherlands Enterprise Agency, significantly strengthening its balance sheet [1][2] - The company is focusing on cost optimization initiatives to enhance operational efficiency and financial flexibility as part of its ongoing strategic review [2] Company Overview - LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company that develops its proprietary Gammabody® platform, which includes bispecific gamma-delta T cell engagers aimed at treating solid tumors and hematologic malignancies [3][4] - The company utilizes engineered bispecific antibodies to selectively target and kill cancer cells by activating Vγ9Vδ2 T cell anti-tumor functions [3] Pipeline and Development - LAVA's pipeline includes three clinical-stage bispecific gamma-delta T cell engagers: LAVA 1266 targeting CD123+ cancers, PF-08046052 targeting EGFR, and JNJ-89853413 targeting hematological cancers [4] - The company also has preclinical programs in development [4]